Log in

OTCMKTS:LBTSFAlmirall Stock Price, Forecast & News

0.00 (0.00 %)
(As of 07/7/2020 04:00 PM ET)
Today's Range
Now: $12.75
50-Day Range
MA: $12.25
52-Week Range
Now: $12.75
Average Volume1,529 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, acne, rosacea, and psoriasis; and central nervous system, cardiovascular, and gastrointestinal diseases. Its strategic brands include ACTIKERALL, BALNEUM, DECODERM, SATIVEX, SKILARENCE, and DECODERM. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone34 93 291 30 00



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive LBTSF News and Ratings via Email

Sign-up to receive the latest news and ratings for LBTSF and its competitors with MarketBeat's FREE daily newsletter.

Almirall (OTCMKTS:LBTSF) Frequently Asked Questions

How has Almirall's stock been impacted by COVID-19 (Coronavirus)?

Almirall's stock was trading at $13.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LBTSF stock has decreased by 1.9% and is now trading at $12.75. View which stocks have been most impacted by Coronavirus.

Has Almirall been receiving favorable news coverage?

News headlines about LBTSF stock have been trending negative recently, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Almirall earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Almirall.

Who are some of Almirall's key competitors?

Who are Almirall's key executives?

Almirall's management team includes the following people:
  • Mr. Jorge Gallardo Ballart, Chairman & Pres (Age 62)
  • Mr. Peter Guenter, CEO, Chairman of Management Board & Exec. Director (Age 56)
  • Mr. David Nieto, CFO, Exec. VP of Fin. & Member of Management Board
  • Mr. Joan Figueras Carreras, Gen. Counsel, Corp. Director, Vice Sec., Member of Mgmt. Board & Non-Voting Director
  • Mr. Eloi Crespo Cervera, VP of Manufacturing & Technical Services and Member of Management Board

What is Almirall's stock symbol?

Almirall trades on the OTCMKTS under the ticker symbol "LBTSF."

How do I buy shares of Almirall?

Shares of LBTSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Almirall's stock price today?

One share of LBTSF stock can currently be purchased for approximately $12.75.

What is Almirall's official website?

The official website for Almirall is www.almirall.com.

How can I contact Almirall?

The company can be reached via phone at 34 93 291 30 00.

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.